Another top exec leaves AstraZeneca
This article was originally published in Scrip
A second top AstraZeneca executive is to leave the company in as many weeks. James Ward-Lilley, currently head of AstraZeneca's respiratory, inflammation and autoimmunity product and portfolio strategy, and a 28-year veteran of the company, is to become CEO of Vectura, a small UK firm focused on lung disease.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.